Updates are available Correction dated 2022-08-08
Click to view Correction: https://doi.org/10.1038/s41591-022-01950-9
-
Authors
Scangos, Katherine W. https://orcid.org/0000-0001-7983-7767
Makhoul, Ghassan S.
Sugrue, Leo P.
Chang, Edward F. https://orcid.org/0000-0003-2480-4700
Krystal, Andrew D. https://orcid.org/0000-0002-6702-781X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (K23NS110962)
NARSAD Young Investigator Grant Ray and Dagmar Dolby Family Fund
Ray and Dagmar Dolby Family Fund
- License Information
-
More Information
Article History
Received: 31 May 2020
Accepted: 12 November 2020
First Online: 18 January 2021
Change Date: 8 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-022-01950-9
Competing interests
: A.D.K. consults for Eisai, Evecxia, Ferring, Galderma, Harmony Biosciences, Idorsia, Jazz, Janssen, Merck, Neurocrine, Pernix, Sage, Takeda, Big Health, Millenium Pharmaceuticals, Otsuka Pharmaceuticals, and Neurawell. All other authors declare no competing interests.
